Key Highlights
- AbbVie approaches finalization of a $10.9 billion cash acquisition of Apogee Therapeutics (APGE)
- The proposed price represents approximately a 60% markup over Apogee’s June 18 close at $90.38
- JPMorgan maintained its Buy rating on ABBV, describing it as strategically sound
- Apogee’s primary compound, zumilokibart, shows potential to compete with Dupixent in dermatitis care
- ABBV shares decreased more than 2% Friday; APGE climbed approximately 2%
AbbVie has entered late-stage negotiations to purchase clinical-stage biotechnology firm Apogee Therapeutics through an all-cash transaction valued at nearly $10.9 billion. The proposed acquisition prices Apogee at approximately 60% above its June 18 closing figure of $90.38. Shares of ABBV declined more than 2% Friday, whereas APGE increased roughly 2% following the disclosure.
Reuters reports indicate an official statement may emerge as soon as Monday, June 22, though both corporations have yet to publicly verify the ongoing discussions.
This transaction would represent AbbVie’s most substantial acquisition since the $63 billion Allergan purchase completed in 2019. However, unlike Allergan—which brought established products and existing revenue streams—Apogee currently lacks any marketed commercial therapies.
Apogee operates as a clinical-stage biotechnology company focused on antibody-based therapeutics for inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The company’s complete development portfolio centers on a single primary asset: zumilokibart.
Zumilokibart works by targeting IL-13, a cytokine responsible for driving inflammatory skin responses in atopic dermatitis patients. Clinical trial results suggest the therapy may necessitate only biannual administration, contrasting sharply with certain current therapies requiring up to 26 yearly injections.
JPMorgan Identifies Strategic Value
JPMorgan analyst Chris Schott maintained his Buy recommendation on ABBV following the transaction news. He characterized the acquisition as strategically coherent, emphasizing AbbVie’s extensive immunology expertise as critical for successfully commercializing zumilokibart upon potential approval.
Schott further highlighted that zumilokibart could establish direct competition with Dupixent, the leading medication jointly marketed by Sanofi and Regeneron that presently commands the atopic dermatitis treatment landscape.
He anticipates AbbVie will implement an extensive development strategy for the compound, noting the acquisition bolsters the company’s late-stage pipeline—a priority area under investor scrutiny.
ABBV maintains a Strong Buy consensus rating on TipRanks, supported by 16 Buy ratings and 5 Hold ratings issued during the previous three months. The average price target stands at $254.71, suggesting approximately 17.65% potential upside.
Pipeline Challenges at AbbVie
AbbVie’s three leading immunology products—Skyrizi, Rinvoq, and Humira—delivered combined revenues of $30.4 billion in 2025, representing 14% year-over-year growth. However, Humira faces persistent erosion from biosimilar alternatives.
While Skyrizi and Rinvoq currently compensate for declining Humira sales, this cushion carries finite duration. AbbVie has pursued a strategy of acquiring early-stage assets instead of awaiting their maturation.
In the previous year, the company committed up to $2.1 billion for Capstan Therapeutics, a Phase 1 autoimmune cell therapy developer. The Apogee acquisition would constitute a substantially larger and earlier-stage investment than previous deals.
Apogee had previously arranged up to $1.3 billion in financing from Blackstone Life Sciences during May to support a Phase 3 clinical trial for zumilokibart. AbbVie would effectively acquire participation in this trial before any regulatory determination occurs.
Apogee’s market capitalization measured approximately $6.8 billion before acquisition reports emerged, having risen nearly 20% year to date. AbbVie’s nearly $11 billion offer represents a valuation based on prospective opportunity rather than existing commercial products.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
